Single-dose Pharmacokinetics of Garenoxacin in Healthy Korean Volunteers |
Shin, Dong-Hoon
(Department of Pharmacology and Clinical Pharmacology & Therapeutics, Seoul National University College of Medicine and Hospital)
Hong, Jeong-Hwa (Department of Pharmacology and Clinical Pharmacology & Therapeutics, Seoul National University College of Medicine and Hospital) Yi, So-Jeong (Department of Pharmacology and Clinical Pharmacology & Therapeutics, Seoul National University College of Medicine and Hospital) Kim, Tae-Eun (Department of Pharmacology and Clinical Pharmacology & Therapeutics, Seoul National University College of Medicine and Hospital) Jang, In-Jin (Department of Pharmacology and Clinical Pharmacology & Therapeutics, Seoul National University College of Medicine and Hospital) Shin, Sang-Goo (Department of Pharmacology and Clinical Pharmacology & Therapeutics, Seoul National University College of Medicine and Hospital) Yu, Kyung-Sang (Department of Pharmacology and Clinical Pharmacology & Therapeutics, Seoul National University College of Medicine and Hospital) |
1 | Krishna G, Kisicki JC, Olsen S, Grasela DM, Wang Z. The Effect of Omeprazole on the Bioavailability and Safety of Garenoxacin in Healthy Volunteers. J Clin Pharmacol, 2007;47:628-632. DOI ScienceOn |
2 | Azoulay-Dupuis E, Bedos JP, Mohler J, Peytavin G, Isturiz R, Moine P, Rieux V, Cherbuliez C, Pechere JC, Fantin B, Kohler T. Activities of Garenoxacin against Quinolone-Resistant Streptococcus pneumoniae Strains In Vitro and in a Mouse Pneumonia Model. Antimicrob Agents Chemother, 2004;48:765-773. DOI ScienceOn |
3 | Ethnic Factors in the Acceptability of Foreign Clinical Data: ICH Harmonised Tripartite Guideline. Ethnic factors in the acceptability of foreign clinical data: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. 1998. |
4 | 가교자료평가 가이드라인, 식품의약품안전청, 2008. |
5 | Bertino J, Fish D. The Safety Profile of the Fluoroquinolones. Clin Ther, 2000;22:798-816. DOI ScienceOn |
6 | Hayakawa H, Fukushima Y, Kato H, Fukumoto H, Kadota T, Yamamoto H, Kuroiwa H, Nishigaki J, Tsuji A. Metabolism and Disposition of Novel Des-Fluoro Quinolone Garenoxacin in Experimental Animals and an Interspecies Scaling of Pharmacokinetic Parameters. Drug Metab Dispos, 2003;31:1409-1418. DOI ScienceOn |
7 | Smith BP, Vandenhende FR, DeSante KA, Farid NA, Welch PA, Callaghan JT, Frgue ST. Confidence Interval Criteria for Assessment of Dose Proportionality. Pharm Res, 2000;17:1278-1283. DOI ScienceOn |
8 | Gajjar DA, Bello A, Ge Z, Christopher L, Grasela DM. Multiple-Dose Safety and Pharmacokinetics of Oral Garenoxacin in Healthy Subjects. Antimicrob Agents Chemother, 2003;47:2256-2263. DOI ScienceOn |
9 | Takagi H, Tanaka K, Tsuda H, Kobayashi H. Clinical studies of garenoxacin. Int J Antimicrob Agents, 2008;32:468-474. DOI ScienceOn |
10 | Pereyre S, Renaudin H, Bebear C, Bebear CM. In vitro activities of the newer quinolones garenoxacin, gatifloxacin, and gemifloxacin against human mycoplasmas. Antimicrob Agents Chemother, 2004;48:3165-3168. DOI ScienceOn |
11 | American Thoracic Society Documents. Guidlines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia. Am J Respir Crit Care Med, 2005;171:388-416. DOI ScienceOn |
12 | Wang Z, Grasela DM, Krishna G. Retrospective Analysis of Electrocardiogram Changes After Administration of Oral or Intravenous Garenoxacin in Five Phase I, Placebo-Controlled Studies in Healthy Volunteers. Clin Ther, 2007;29:1098-1106. DOI ScienceOn |
13 | Jones RN, Sader HS, Stilwell MG, Fritsche TR. Garenoxacin activity against isolates form patients hospitalized with communityacquired pneumonia and multidrug-resistant Streptococcus pneumonia. Diagn Microbiol Infect Dis, 2007;58:1-7. DOI ScienceOn |
14 | Andriole VT. The Quinolones: Past, Present, and Future. Clin Infect Dis, 2005;41:S113-S119. DOI ScienceOn |
15 | Zhanel GG, Fontaine S, Adam H, Schurek K, Mayer M, Noreddin AM, Gin AS, Rubinstein E, Hoban DJ. A Review of New Fluoroquinolones. Treat Respir Med, 2006;5:437-465. DOI |
16 | Investigator's Brochure: 동아 Garenoxacin 정. 동아제약주식회사. 2007. |
17 | Mandell LA, Wundrink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Musher DM, Niederman MS, Niederman MS, Torres A, Whitney CG. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Clin Infect Dis, 2007;44:S27-S72. DOI ScienceOn |